|
Q1 FY2023
As of Jan 31, 2023
|
Q4 FY2022
As of Oct 31, 2022
|
Q3 FY2022
As of Jul 31, 2022
|
Q2 FY2022
As of Apr 30, 2022
|
Q1 FY2022
As of Jan 31, 2022
|
Q4 FY2021
As of Oct 31, 2021
|
Q3 FY2021
As of Jul 31, 2021
|
Q2 FY2021
As of Apr 30, 2021
|
Q1 FY2021
As of Jan 31, 2021
|
Q4 FY2020
As of Oct 31, 2020
|
Q3 FY2020
As of Jul 31, 2020
|
Q2 FY2020
As of Apr 30, 2020
|
Q1 FY2020
As of Jan 31, 2020
|
Q4 FY2019
As of Oct 31, 2019
|
Q3 FY2019
As of Jul 31, 2019
|
Q3 FY2018
As of Jul 31, 2018
|
Q4 FY2018
As of Oct 31, 2018
|
Q1 FY2019
As of Jan 31, 2019
|
Q2 FY2019
As of Apr 30, 2019
|
Q2 FY2018
As of Apr 30, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders' Deficit | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Convertible Promissory Note (Related Party) | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Due to related party | ||||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Deficit | ||||||||||||||||||||
| 31,518,466 issued and outstanding | ||||||||||||||||||||
| Common stock: 750,000,000 shares authorized; $0.001 par value 31,518,466 issued and outstanding | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders' Deficit | ||||||||||||||||||||
Loading...
